SEC Form 4 · accession 0001140361-17-026640
NRC HEALTH · NRC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John N Nunnelly
Director
Period of report
Jun 27, 2017
Accepted (ET)
Jun 29, 2017 · 3:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000070487
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 27, 2017 | M | 4,319 | $7.61 | A | 33,019 | D | |
| Class A Common Stock | Jun 27, 2017 | F | 1,219 | $26.95 | D | 31,800 | D | |
| Class A Common StockF1 | Jun 27, 2017 | S | 3,100 | $27.0558 | D | 28,700 | D | |
| Class A Common Stock | Jun 28, 2017 | M | 2,718 | $7.61 | A | 31,418 | D | |
| Class A Common Stock | Jun 28, 2017 | F | 759 | $27.25 | D | 30,659 | D | |
| Class A Common StockF2 | Jun 28, 2017 | S | 1,959 | $27.2425 | D | 28,700 | D | |
| Class B Common Stock | holding | — | — | — | 3,900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy) | $7.61 | Jun 27, 2017 | M | 4,319 | D | May 7, 2011 | May 7, 2020 | Class A Common Stock | 4,319 | 28,854 | D |
| Director Stock Option (Right to Buy) | $7.61 | Jun 28, 2017 | M | 2,718 | D | May 7, 2011 | May 7, 2020 | Class A Common Stock | 2,718 | 26,136 | D |
| Director Stock Option (Right to Buy) | $9.73 | holding | — | — | — | May 6, 2012 | May 6, 2021 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $13.81 | holding | — | — | — | May 11, 2013 | May 11, 2022 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $16.89 | holding | — | — | — | May 9, 2014 | May 9, 2023 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $14.95 | holding | — | — | — | May 8, 2015 | May 8, 2024 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $14.21 | holding | — | — | — | May 7, 2016 | May 7, 2025 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $14.19 | holding | — | — | — | May 11, 2017 | May 11, 2026 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $24.35 | holding | — | — | — | May 9, 2018 | May 9, 2027 | Class A Common Stock | 36,000 | 36,000 | D |
| Director Stock Option (Right to Buy) | $16.80 | holding | — | — | — | May 7, 2011 | May 7, 2020 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $19.98 | holding | — | — | — | May 6, 2012 | May 6, 2021 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $26.10 | holding | — | — | — | May 11, 2013 | May 11, 2022 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $30.72 | holding | — | — | — | May 9, 2014 | May 9, 2023 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $43.91 | holding | — | — | — | May 8, 2015 | May 8, 2024 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $34.50 | holding | — | — | — | May 7, 2016 | May 7, 2025 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $37.78 | holding | — | — | — | May 11, 2017 | May 11, 2026 | Class B Common Stock | 6,000 | 6,000 | D |
| Director Stock Option (Right to Buy) | $44.47 | holding | — | — | — | May 9, 2018 | May 9, 2027 | Class B Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1The price in Column 4 is a weighted average price. The prices actually received ranged from $27.00 to $27.15. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
- F2The price in Column 4 is a weighted average price. The prices actually received ranged from $27.20 to $27.35. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.